drugset

drugset / Trial / NCT04596488

Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

NCT04596488 ↗

Completed 25 enrolled Peking Union Medical College Hospital CAMS Initiative for Innovative Medicine · collab National Key Technologies R&D Program for the 12th Five-year Plan · collab National Key Technologies R&D Program for the 13th Five-year Plan · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-naïve Chinese HIV-infected patients.

Timeline

Start: 2017-06-01
Primary completion: 2018-12-30
Completion: 2019-12-30

Publications

Xu L, Peng W, Song X, Li Y, Han Y, Zhu T, Fu Q, Du X, Cao W, Li T. Pharmacodynamics of efavirenz 400 mg in treatment-naive Chinese HIV-infected patients in a prospective cohort study. BMC Infect Dis. 2021 Jan 23;21(1):112. doi: 10.1186/s12879-021-05802-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efavirenz	Other / unclassified	400 mg	—

Indications